Showing results (181-190 of 245) with videos related to
Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean-Christophe Pignon, Opeyemi Jegede, Sachet A Shukla, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2020
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell CarcinomaMiriam Ficial, Opeyemi A Jegede, Miriam Sant'Angelo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma PatientsThomas Denize, Opeyemi A Jegede, Sayed Matar, et al.Nature Cell Biology|August 17, 2023
KDM6A epigenetically regulates subtype plasticity in small cell lung cancerLeslie Duplaquet, Yixiang Li, Matthew A Booker, et al.Nature Metabolism|February 6, 2025
Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinomaJiao Li, Kaimeng Huang, Meha Thakur, et al.Cancer Discovery|March 15, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanibNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.Nature Genetics|January 17, 2018
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancerMing Chen, Jiangwen Zhang, Katia Sampieri, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell CarcinomaNizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.Developmental Cell|August 27, 2025
Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancerDeli Hong, Ying Lyu, Richa Nayak, et al.The Oncologist|June 27, 2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following ImmunotherapyJustine Panian, Ava Saidian, Kevin Hakimi, et al.Pageof 25